The 8th RNAi-Based Therapeutics Summit returns to Boston from January 27-29, 2027, bringing together more than 90 industry experts working across oligonucleotide synthesis, chemistry, biology, molecular design, targeted delivery, translational development, and commercialization. The meeting will provide a focused forum for advancing safer, more potent RNAi therapeutics and expanding their reach beyond traditional liver-directed applications.
Attendees will hear the latest developments in antibody-oligonucleotide conjugates, aptamer-siRNA conjugates, nanoparticles, tetravalent siRNAs, bispecific RNAi approaches, cell-specific delivery, and multi-target silencing strategies. Scientific presentations and panel discussions will examine how developers can cross the blood-brain barrier, target skeletal muscle and adipose tissue, deliver genetic medicines to the kidney, improve retinal gene silencing, and address complex tumor biology.
Two interactive pre-conference workshops will focus on identifying and validating receptors for selective extrahepatic delivery and modifying oligonucleotide chemistry to improve stability, circulation time, tissue exposure, and PK/PD performance. The wider program will also address safety, clinical translation, commercialization, investment, and strategic partnerships, helping developers progress promising candidates while reducing technical and commercial risk.
Featuring experts from organizations including Sanegene Bio, Thalia Therapeutics, Eli Lilly and Company, Novo, Bayer, Bonito Biosciences, Valaya Bio, Judo Bio, UMass Chan Medical School, and Trinetra Therapeutics, the summit offers an intimate environment for scientific exchange and meaningful collaboration. Attendees will leave with practical insights and valuable connections to support the development of the next generation of RNAi medicines.
To know more visit: https://ter.li/ger5rzdy